With approximately 1150 new cases annually in Switzerland, urothelial carcinoma of the urinary bladder is one of the most common cancers of older age. Particularly in the metastatic setting, it has become after a long lull in therapy. For example, checkpoint inhibitors are now the established standard of care in the second-line setting, and avelumab was recently approved for maintenance therapy in the first-line setting.
This content is machine-translated. Please contact us if you need professional translation services.
Autoren
- Prof. Dr. med. Christian Wülfing
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Coronary heart disease and type 2 diabetes
Relationship between baseline FFA values and all-cause mortality.
- Esophagus
Therapy of esophageal carcinoma – an overview
- Visceral Surgery Update - Part 1
Upper gastrointestinal tract and robotic visceral surgery
- Case reports: Pityriasis rubra pilaris (PRP)
Supposedly therapy-resistant PRP responded to biologic treatment
- Polyneuropathies
Disorders of brain, spinal cord and nerve function
- Pulmonary arterial hypertension beyond the guideline.
IPAH or what else? – IPAH with pulmonary comorbidity
- Disease of the subcutaneous adipose tissue
Lipedema – a painful fatty tissue disease of the extremities in women
- Rare diseases